HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

Benzinga · 2d ago
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.